🔎 Trials Near Me

Home › Myelodysplastic Syndromes › Texas › Houston

Myelodysplastic Syndromes clinical trials in Houston, TX

43 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

RecruitingPhase 1
  • University of Texas MD Anderson Cancer Center, Houston
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecruitingPhase 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06548230

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

RecruitingPhase 1/2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03661307

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

RecruitingPhase 1/2
  • MD Anderson, Houston
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

RecruitingPhase 3
  • The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
  • LUMI Research, Houston
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07422480

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

RecruitingPhase 1
  • M D Anderson Cancer Center, Houston
Ages 1 and older · All sexes · Updated Sep 18, 2026 · NCT03630991

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

RecruitingPhase 1/2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

RecruitingPhase 1/2
  • Md Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04771130

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

RecruitingPhase 2Healthy volunteers welcome
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06566742

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06616636

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

RecruitingPhase 1/2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05010122

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

RecruitingPhase 3
  • MD Anderson Cancer Centre, Houston
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06465953

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT04493164

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RecruitingPhase 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

RecruitingPhase 3
  • U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06499285

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

RecruitingPhase 2
  • Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT04419649

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

RecruitingPhase 2/3Healthy volunteers welcome
  • M D Anderson Cancer Center, Houston
Ages 18 to 70 · All sexes · Updated Aug 11, 2026 · NCT04708054

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT05308264

Personalized NK Cell Therapy in CBT

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 15 to 80 · All sexes · Updated Jul 30, 2026 · NCT02727803

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

RecruitingPhase 2
  • University of Texas MD Anderson Cancer Center, Houston
Ages 60 and older · All sexes · Updated Jul 16, 2026 · NCT01515527

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT02074839

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

RecruitingPhase 2
  • GSK Investigational Site, Houston
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT06847867

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

RecruitingPhase 1
  • MD Anderson, Houston
Ages 18 and older · All sexes · Updated May 28, 2026 · NCT04953897

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

RecruitingPhase 1
  • MD Anderson, Houston
Ages 18 and older · All sexes · Updated May 28, 2026 · NCT04953910

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RecruitingPhase 2/3
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05732103

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Mar 25, 2026 · NCT07107126

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

RecruitingPhase 1/2
  • MDACC, Houston
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RecruitingPhase 1
  • MD Anderson, Houston
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT05143996

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

RecruitingPhase 1Healthy volunteers welcome
  • M.D. Anderson Cancer Center, Department of Leukemia, Houston
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT05986240

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Houston
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

RecruitingPhase 1
  • The University of Texas M.D. Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196

Study of REM-422 in Patients With AML or Higher Risk MDS

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 23, 2025 · NCT06297941

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Mar 20, 2024 · NCT04243785

About Myelodysplastic Syndromes

Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.

More about Myelodysplastic Syndromes on MedlinePlus

Myelodysplastic Syndromes trials in other cities

Other studies in Houston

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.